INSMED INC Increase (Decrease) in Other Operating Liabilities
INSMED INC (INSM) reported Increase (Decrease) in Other Operating Liabilities of -$1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-06
- INSMED INC increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was -$744.00K.
- INSMED INC increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was -$497.00K.
- INSMED INC increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was -$914.00K.
- INSMED INC increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was -$1.10M.
- INSMED INC increase (decrease) in other operating liabilities for fiscal 2025 was -$4.99M.
- INSMED INC increase (decrease) in other operating liabilities for fiscal 2024 was -$11.95M.
- INSMED INC increase (decrease) in other operating liabilities for fiscal 2023 was -$10.99M.
- INSMED INC increase (decrease) in other operating liabilities for fiscal 2022 was -$12.58M.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$744.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.24M 10-Q · filed 2026-08-06 | -$2.15M derived: sum of 3 quarters · filed 2026-08-06 | -$3.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$497.00K 10-Q · filed 2026-05-07 | -$1.41M derived: sum of 2 quarters · filed 2026-05-07 | -$2.51M derived: sum of 3 quarters · filed 2026-05-07 | -$3.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$914.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$2.01M derived: sum of 2 quarters · filed 2026-02-19 | -$2.83M derived: sum of 3 quarters · filed 2026-08-06 | -$4.99M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$1.91M derived: sum of 2 quarters · filed 2026-08-06 | -$4.08M 10-Q · filed 2025-10-30 | -$8.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$815.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.98M 10-Q · filed 2026-08-06 | -$7.56M derived: sum of 3 quarters · filed 2026-08-06 | -$8.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$2.17M 10-Q · filed 2026-05-07 | -$6.75M derived: sum of 2 quarters · filed 2026-05-07 | -$7.37M derived: sum of 3 quarters · filed 2026-05-07 | -$7.97M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$5.20M derived: sum of 2 quarters · filed 2026-02-19 | -$5.80M derived: sum of 3 quarters · filed 2026-02-19 | -$11.95M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$620.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$1.22M derived: sum of 2 quarters · filed 2025-10-30 | -$7.37M 10-Q · filed 2025-10-30 | -$12.73M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$604.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$6.75M 10-Q · filed 2025-08-07 | -$12.11M derived: sum of 3 quarters · filed 2026-02-19 | -$12.58M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$6.14M 10-Q · filed 2025-05-08 | -$11.51M derived: sum of 2 quarters · filed 2026-02-19 | -$11.97M derived: sum of 3 quarters · filed 2026-02-19 | -$15.71M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$5.83M derived: sum of 2 quarters · filed 2026-02-19 | -$9.57M derived: sum of 3 quarters · filed 2026-02-19 | -$10.99M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$468.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$4.20M derived: sum of 2 quarters · filed 2024-10-31 | -$5.63M 10-Q · filed 2024-10-31 | $3.14M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | -$3.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$5.16M 10-Q · filed 2024-08-08 | $3.61M derived: sum of 3 quarters · filed 2025-02-20 | -$1.21M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$1.42M 10-Q · filed 2024-05-09 | $7.35M derived: sum of 2 quarters · filed 2025-02-20 | $2.53M derived: sum of 3 quarters · filed 2025-02-20 | $8.97M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $8.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $3.95M derived: sum of 2 quarters · filed 2025-02-20 | $10.39M derived: sum of 3 quarters · filed 2025-02-20 | -$12.58M 10-K · filed 2025-02-20 |
| 2022-09-30 | -$4.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $1.63M derived: sum of 2 quarters · filed 2023-10-26 | -$21.35M 10-Q · filed 2023-10-26 | |
| 2022-06-30 | $6.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$16.53M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | -$22.98M 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | -$14.26M 10-Q · filed 2022-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |